Verity Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.79M | Buy |
21,861
+447
| +2% | +$55.8K | 1.17% | 19 |
|
|
2025
Q4 | $2.61M | Buy |
21,414
+1,227
| +6% | +$141K | 1.12% | 19 |
|
|
2025
Q3 | $2.02M | Buy |
20,187
+517
| +3% | +$46.6K | 0.66% | 37 |
|
|
2025
Q2 | $1.63M | Sell |
19,670
-132
| -0.7% | -$10.5K | 0.78% | 35 |
|
|
2025
Q1 | $1.61M | Buy |
19,802
+117
| +0.6% | +$10.5K | 0.65% | 46 |
|
|
2024
Q4 | $1.77M | Sell |
19,685
-404
| -2% | -$39.1K | 1% | 25 |
|
|
2024
Q3 | $1.98M | Buy |
20,089
+179
| +0.9% | +$17.6K | 0.75% | 30 |
|
|
2024
Q2 | $1.85M | Buy |
19,910
+1,765
| +10% | +$158K | 0.72% | 35 |
|
|
2024
Q1 | $1.72M | Buy |
18,145
+777
| +4% | +$72.1K | 0.96% | 21 |
|
|
2023
Q4 | $1.55M | Buy |
17,368
+140
| +0.8% | +$10.4K | 0.99% | 22 |
|
|
2023
Q3 | $1.26M | Buy |
17,228
+1,266
| +8% | +$101K | 0.93% | 26 |
|
|
2023
Q2 | $1.33M | Buy |
15,962
+203
| +1% | +$17K | 0.99% | 21 |
|
|
2023
Q1 | $1.2M | Buy |
15,759
+782
| +5% | +$64.9K | 0.72% | 39 |
|
|
2022
Q4 | $1.24M | Buy |
14,977
+121
| +0.8% | +$9.8K | 1.06% | 25 |
|
|
2022
Q3 | $1.18M | Buy |
+14,856
| New | +$1.25M | 1.22% | 16 |
|
|
2022
Q1 | $1.26M | Buy |
14,052
+2,642
| +23% | +$244K | 0.8% | 29 |
|
|
2021
Q4 | $1.28M | Sell |
11,410
-127
| -1% | -$15.3K | 0.75% | 23 |
|
|
2021
Q3 | $1.45M | Buy |
11,537
+192
| +2% | +$24.7K | 0.94% | 19 |
|
|
2021
Q2 | $1.54M | Buy |
11,345
+380
| +3% | +$50K | 0.84% | 22 |
|
|
2021
Q1 | $1.49M | Sell |
10,965
-1,755
| -14% | -$263K | 0.89% | 23 |
|
|
2020
Q4 | $1.79M | Sell |
12,720
-3,140
| -20% | -$402K | 1.25% | 18 |
|
|
2020
Q3 | $1.77M | Buy |
15,860
+1,400
| +10% | +$157K | 1.34% | 11 |
|
|
2020
Q2 | $1.62M | Sell |
14,460
-2,754
| -16% | -$271K | 1.49% | 10 |
|
|
2020
Q1 | $1.33M | Sell |
17,214
-1,330
| -7% | -$118K | 1.68% | 14 |
|
|
2019
Q4 | $1.76M | Sell |
18,544
-1,193
| -6% | -$103K | 1.76% | 4 |
|
|
2019
Q3 | $1.5M | Sell |
19,737
-1,278
| -6% | -$106K | 1.58% | 8 |
|
|
2019
Q2 | $1.84M | Sell |
21,015
-205
| -1% | -$17.5K | 2.07% | 6 |
|
|
2019
Q1 | $1.92M | Sell |
21,220
-239
| -1% | -$20.3K | 2.22% | 7 |
|
|
2018
Q4 | $1.54M | Buy |
21,459
+1,757
| +9% | +$142K | 2.06% | 11 |
|
|
2018
Q3 | $1.89M | Sell |
19,702
-5,892
| -23% | -$571K | 1.86% | 11 |
|
|
2018
Q2 | $2.44M | Buy |
25,594
+22,234
| +662% | +$2.04M | 2.2% | 8 |
|
|
2018
Q1 | $295K | Sell |
3,360
-719
| -18% | -$65.6K | 0.27% | 74 |
|
|
2017
Q4 | $381K | Buy |
4,079
+42
| +1% | +$3.52K | 0.29% | 59 |
|
|
2017
Q3 | $338K | Buy |
+4,037
| New | +$324K | 0.26% | 65 |
|
Other funds holding XBI
Verity Asset Management's XBI Position: Q1 2026 in Review
Verity Asset Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.1% in Q1 2026, buying an estimated $55.8K and bringing the position to 21,861 shares worth $2.79M. The position accounts for 1.17% of the portfolio, ranked #19.
Verity Asset Management first reported a position in XBI in Q3 2017 and has held it in 34 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Verity Asset Management held 21,861 shares of State Street SPDR S&P Biotech ETF worth $2.79M as of Q1 2026.
- Verity Asset Management bought 447 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $55.8K.
- State Street SPDR S&P Biotech ETF made up 1.17% of Verity Asset Management's portfolio in Q1 2026, its #19 holding.
- Verity Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and has held it in 34 quarters since.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Verity Asset Management's 13F filing for Q1 2026, filed 21 Apr 2026.